Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tobramycin inhalation solution - Novartis

Drug Profile

Tobramycin inhalation solution - Novartis

Alternative Names: TOBI; TOBI NextGen; TOBI® solution; Tobramycin aerosol - Chiron

Latest Information Update: 27 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • No development reported Pneumonia
  • Discontinued Bronchiectasis; Respiratory tract infections; Tuberculosis

Most Recent Events

  • 20 Sep 2019 No development reported - Phase-II for Pneumonia in Germany (Inhalation)
  • 31 Aug 2018 Tobramycin inhalation solution market licensed to Mylan worldwide
  • 31 Jul 2017 Discontinued - Phase-III for Cystic fibrosis-associated respiratory tract infections (In infants, In children) in Romania, Egypt, Poland, Italy, Germany, Greece, France, Russia, Switzerland, Hungary and Canada (Inhalation), because not listed on Novartis pipeline, December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top